Combined vaccination with b cell peptides targeting her-2/neu and immune checkpoints as emerging treatment option in cancer

HIGHLIGHTS

• who: Joshua Tobias and colleagues from the Center for Pathophysiology, Infectiology and Immunology, Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria have published the research: Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer, in the Journal: (JOURNAL)
• what: The evaluation of the safety, immunogenicity and tolerability of vaccination with a PD-1 peptide (PD-1-Vaxx) is the aim of the ongoing phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT04432207).
• how: On the basis of the results . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.